CAR T cells plus radiation for follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of a CAR T-cell therapy (Axicabtagene Ciloleucel) with radiation therapy for people with follicular lymphoma that has come back or not responded to multiple treatments. The goal is to see if adding radiation can make the CAR T cells work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have follicular lymphoma (grades 1-3A) that has not responded to or returned after at least two prior treatments.
- You have at least one tumor that is 1 centimeter or larger and can be seen on a scan or exam.
- Your organs (kidneys, liver, heart, lungs) and blood counts meet safety levels (your doctor will help confirm).
- You are not pregnant and agree to use birth control if needed.
- You do not have another active cancer requiring treatment (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests whether a low dose of total body radiation combined with CAR T-cell therapy can help people with certain types of lymphoma or multiple myeloma that have come back or stopped responding to other treatments. It may be an option for patients whose cancer is hard to treat with standard therapies.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.